PDGFRB and neoplasm: Sorafenib reduces the activity of Raf-1 and B-Raf serine/threonine kinases, inhibits the activity of tyrosine kinase receptors in VEGFRs, and regulates the intervention of PDGFR-b, Ret, and c-Kit, which inhibit tumor growth and angiogenesis [149,150,151].